DENND2B: A Potential Drug Target for Cancer (G6764)

Target Name: DENND2B

NCBI ID: G6764

DENND2B

DENND2B: A Potential Drug Target for Cancer

DENND2B (short for double helix N-terminal domain dependent protein 2B) is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

Recent studies have identified DENND2B as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. DENND2B has been shown to be highly expressed in many types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to play a role in the development of pancreatic cancer.

One of the key reasons for the potential of DENND2B as a drug target is its involvement in the regulation of the cell cycle. The cell cycle is the process by which a cell grows and replicates, and it is a critical factor in the development and progression of many diseases. DENND2B is involved in the regulation of the cell cycle at multiple levels, including the G1 phase, the S phase, and the G2 phase.

Studies have shown that DENND2B plays a key role in the regulation of the G1 phase of the cell cycle. During the G1 phase, cells prepare for cell division by producing more DNA and increasing their size. DENND2B is involved in the regulation of the production of mitotic spindle proteins, which are important for the proper attachment of the mitotic spindle during the G1 phase.

In addition to its role in the regulation of the cell cycle, DENND2B has also been shown to play a role in the development and progression of cancer. Studies have shown that DENND2B is often overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This increase in the expression of DENND2B has been shown to contribute to the development and progression of these diseases.

DENND2B is also involved in the regulation of the S phase of the cell cycle, which is the phase of cell growth where DNA is replicated. Studies have shown that DENND2B plays a key role in the regulation of DNA replication during the S phase. DENND2B is involved in the production of DNA replication proteins, which are important for the proper replication of DNA during the S phase.

In addition to its role in the regulation of the cell cycle, DENND2B has also been shown to play a role in the development and progression of cancer. Studies have shown that DENND2B is often overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This increase in the expression of DENND2B has been shown to contribute to the development and progression of these diseases.

Finally, DENND2B is also involved in the regulation of the G2 phase of the cell cycle, which is the phase of cell growth where the cell prepares for cell division. Studies have shown that DENND2B plays a key role in the regulation of the G2 phase of the cell cycle. DENND2B is involved in the production of microtubules, which are important for the proper movement of the cell during the G2 phase.

In conclusion, DENND2B is a protein that is involved in the regulation of the cell cycle and has been shown to play a key role in the development and progression of many diseases, including cancer. Its potential as a drug target makes it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of DENND2B in the regulation of the cell cycle and its potential as a drug target.

Protein Name: DENN Domain Containing 2B

Functions: May be involved in cytoskeletal organization and tumorogenicity. Seems to be involved in a signaling transduction pathway leading to activation of MAPK1/ERK2. Plays a role in EGFR trafficking from recycling endosomes back to the cell membrane (PubMed:29030480)

The "DENND2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DENND2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets